Industry News
Jobs lost as GroPep facility shuts
More than 30 staff at the former Biotech Australia (BA) will lose their jobs in the operational restructure planned by Adelaide growth factor company GroPep. [ + ]
Public consultation on research priorities
Australians are being asked to comment on the future for research spending as part of a community consultation initiative.
[ + ]NSW govt awards aim to reverse the 'brain-drain'
Garvan Institute neurobiologist Dr Bryce Vissel is one of the first recipients of the NSW government's inaugural BioFirst Awards. [ + ]
Protein gel offers hope to childless
A pre-intercourse gel derived from a protein found in sperm could prove the key to fertility for thousands of childless couples. [ + ]
A new name for MicroMedical
Artificial heart developer MicroMedical Industries has announced it plans to change its name to Ventracor. [ + ]
Farmacule sets down roots for new technology
A two-pronged business strategy is showing promise for Australia's leading player in molecular farming, Farmacule Bioindustries. [ + ]
Meditech announces positive HyDOX results
Meditech Research has announced that its pre-clinical animal studies for anti-cancer drug HyDOX showed a three-fold reduction of heart damage. [ + ]
IDT not concerned by AstraZeneca decision on cancer drug
Pharmaceutical manufacturer Institute of Drug Technology may pursue direct talks with the UK developer of an early-stage anti-cancer drug after licensee AstraZeneca dumped the project. [ + ]
Anadis claims oral vaccine delivery breakthrough
Claims of a breakthrough technique for delivering oral vaccines and pharmaceuticals to the stomach wall have been made by Melbourne company Anadis. [ + ]
No GE-free zones for Victoria
Agriculture Victoria has confirmed that it will not be seeking to create genetic engineering-free (GE-free) zones in Victoria, at least for the time being. [ + ]
Bio 2002 exodus begins
An exodus of Australian bioscience professionals heading for Toronto and the start of the Bio 2002 conference and exhibition has begun. [ + ]
EpiTan signs with US group to develop formula
Tanning drug developer EpiTan has signed a collaborative agreement with a United State research institute to create a sustained-release version of its formulation. [ + ]
Device network, AusBiotech join forces
The Medical Device Network (MDN) has joining forces with peak body AusBiotech to officially become a program of the industry organisation. [ + ]
Progen PI-88 trials proliferate
Australian biotech Progen Industries has won ethics approval to launch a Phase I human trial for its anti-cancer drug candidate PI-88 in conjunction with established chemotherapy agent Taxotere. [ + ]
Nextec BioSciences and council combine to foster biotech
Investment banking group Nextec BioSciences has joined forces with the Melbourne City Council to establish an entrepreneurial incubator for biobusinesses. [ + ]
